Trial Profile
Tolerance and Activity Assessment of High Doses of Favipiravir in Male Survivors With Ebola Virus in the Semen
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 24 Oct 2018
Price :
$35
*
At a glance
- Drugs Favipiravir (Primary)
- Indications Ebola virus infections
- Focus Adverse reactions
- Acronyms FORCE
- 17 Oct 2018 Status changed from recruiting to discontinued.
- 03 May 2016 Status changed from not yet recruiting to recruiting.
- 18 Apr 2016 New trial record